Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind PK, Efficacy, Safety and Immunogenicity Comparison of ABP 234 vs Keytruda (Pembrolizumab) in Advanced Non-squamous NSCLC
jRCT2061240025Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ABP 234 with Keytruda (pembrolizumab) (2 arms). Primary endpoints: AUC21d of ABP 234 and AUCtau_ss of ABP 234. Started Sep 2024; status: active, not recruiting.
02
Drugs
abp 234pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061240025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240025.